Healthcare solutions company Evolent Health (NYSE: EVH) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with sales up 46.9% year on year to $652.5 million. The company’s full-year revenue guidance of $2.65 billion at the midpoint came in 5.9% above analysts’ estimates. Its non-GAAP profit of $0.02 per share was significantly above analysts’ consensus estimates.

Is now the time to buy Evolent Health? Find out by accessing our full research report, it’s free.

Seth Blackley, Co-Founder and Chief Executive Officer of Evolent stated, "We believe our results for the second quarter of 2026, our updated 2026 guidance and our 2027 outlook all demonstrate that Evolent is delivering strong growth, profitability and cash flow. We are confident in our emerging AI-led operational model that we believe allows us to deliver excellent client and clinical outcomes, while being highly disciplined with our cost structure."

Company Overview

Founded in 2011 to transform how healthcare is delivered to patients with complex needs, Evolent Health (NYSE: EVH) provides specialty care management services and technology solutions that help health plans and providers deliver better care for patients with complex conditions.

Revenue Growth

A company’s long-term sales performance can indicate its overall quality. Even a bad business can shine for one or two quarters, but a top-tier one grows for years. Luckily, Evolent Health’s sales grew at an impressive 17.8% compounded annual growth rate over the last five years. Its growth beat the average healthcare company and shows its offerings resonate with customers.

Long-term growth is the most important, but within healthcare, a half-decade historical view may miss new innovations or demand cycles. Evolent Health’s recent performance marks a sharp pivot from its five-year trend as its revenue has shown annualized declines of 5.6% over the last two years.

We can better understand the company’s revenue dynamics by analyzing its number of average lives on platform, which reached 75.64 million in the latest quarter. Over the last two years, Evolent Health’s average lives on platform averaged 3.2% year-on-year growth. Because this number is better than its revenue growth, we can see the company’s average selling price decreased.

This quarter, Evolent Health reported magnificent year-on-year revenue growth of 46.9%, and its $652.5 million of revenue beat Wall Street’s estimates by 9.4%.

Looking ahead, sell-side analysts expect revenue to grow 37% over the next 12 months, an improvement versus the last two years. This projection is eye-popping and indicates its newer products and services will catalyze better top-line performance.

ALSO WORTH WATCHING: Nvidia’s Quiet Partner. Nvidia’s chips cost a hundred grand. The connectors that make them work cost even more. One company makes them all.

Every AI server needs specialized infrastructure the chip companies don’t make. High-speed cables. Power connectors. Thermal sensors. This 90-year-old company built a monopoly on it. The AI boom just started. This stock is still flying under the radar. Claim The Stock Ticker Here for FREE.

Adjusted Operating Margin

Adjusted operating margin is an important measure of profitability as it shows the portion of revenue left after accounting for all core expenses — everything from the cost of goods sold to advertising and wages. It’s also useful for comparing profitability across companies because it excludes non-recurring expenses, interest on debt, and taxes.

Evolent Health’s adjusted operating margin has more or less stayed the same over the last 12 months , averaging 4.9% over the last five years. This profitability was paltry for a healthcare business and caused by its suboptimal cost structure.

Looking at the trend in its profitability, Evolent Health’s adjusted operating margin of 3.6% for the trailing 12 months may be around the same as five years ago, but it has decreased by 3.3 percentage points over the last two years. This dynamic unfolded because it failed to adjust its fixed costs while demand fell.

This quarter, Evolent Health’s breakeven margin was 0.9%, down 5.4 percentage points year on year. This contraction shows it was less efficient because its expenses grew faster than its revenue.

Earnings Per Share

Revenue trends explain a company’s historical growth, but the long-term change in earnings per share (EPS) points to the profitability of that growth — for example, a company could inflate its sales through excessive spending on advertising and promotions.

Evolent Health’s full-year EPS flipped from negative to positive over the last five years. This is encouraging and shows it’s at a critical moment in its life.

In Q2, Evolent Health reported adjusted EPS of $0.02, up from negative $0.10 in the same quarter last year. This print easily cleared analysts’ estimates, and shareholders should be content with the results. Over the next 12 months, Wall Street expects Evolent Health’s full-year EPS to grow 154% from $0.13 to $0.33.

Key Takeaways from Evolent Health’s Q2 Results

It was good to see Evolent Health beat analysts’ EPS expectations this quarter. We were also excited its revenue outperformed Wall Street’s estimates by a wide margin. Zooming out, we think this was a solid print. The stock traded up 18.2% to $3.64 immediately after reporting.

Indeed, Evolent Health had a rock-solid quarterly earnings result, but is this stock a good investment here? We think that the latest quarter is only one piece of the longer-term business quality puzzle. Quality, when combined with valuation, can help determine if the stock is a buy. We cover that in our actionable full research report which you can read here (it’s free).